192 related articles for article (PubMed ID: 28144840)
1. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
3. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
[TBL] [Abstract][Full Text] [Related]
4. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
[TBL] [Abstract][Full Text] [Related]
5. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
6. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
7. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
10. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
[TBL] [Abstract][Full Text] [Related]
11. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis.
Zhong S; Zhu X; Zhao L; Song Y; Yu J; Zheng Z; Zang B
Pharm Res; 2021 Jan; 38(1):67-77. PubMed ID: 33404989
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
14. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
[TBL] [Abstract][Full Text] [Related]
15. Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.
Lu X; Xu G; Chen L; Fan J; Li M; Zhu L
Eur J Clin Pharmacol; 2020 May; 76(5):695-702. PubMed ID: 32047965
[TBL] [Abstract][Full Text] [Related]
16. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
17. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
18. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
19. Assessment of micafungin dosage regimens against
Wei XC; Zhao MF; Xiao X
J Chemother; 2023 Dec; 35(8):721-729. PubMed ID: 37190751
[TBL] [Abstract][Full Text] [Related]
20. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]